Wat is de prijs voor Metagenomi, Inc. Common Stock (MGX)

Het prijs van Metagenomi, Inc. Common Stock (MGX) is $1.21

Wat is de marktkapitalisatie voor Metagenomi, Inc. Common Stock (MGX)

Marktkapitalisatie voorMetagenomi, Inc. Common Stock (MGX) is $45.55M

Metagenomi, Inc. Common Stock (MGX) WPA

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Jaar	EPS	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

EPS

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	EPS	EPS-verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$2.98	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	$-7.98	-	US

Bedrijf

EPS

EPS-verschil

Land